Bioventus reports Q1 EPS 8c, consensus 2c

Reports Q1 revenue $123.876M, consensus $122.71M. “Our Bioventus (BVS) team delivered solid results to start the year and we are making substantial progress with executing our strategic plan,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “We remain well positioned to navigate the uncertain macro-environment while achieving above-market revenue growth through a multitude of diverse growth drivers, enhancing profitability and accelerating cash flow to create significant shareholder value.”